On November 11, 2000, the U.S. Food and Drug Administration (FDA) issued an advisory concerning the safety of phenylpropanolamine (PPA). Wyeth Consumer Healthcare immediately stopped shipping all PPA-containing products, removed these products from store shelves and began shipping reformulated products without PPA.

Products containing PPA were initially reformulated with pseudoephedrine, an ingredient regarded by the FDA as safe and effective to relieve nasal congestion. Most recently, Wyeth Consumer Healthcare’s pseudoephedrine-containing products have been reformulated with phenylephrine (see pseudoephedrine information here).